The Chemical Biology Core assists researchers in identifying and optimizing chemical probes and new lead compounds that can aid drug discovery &development and ultimately provide therapeutic benefit to cancer patients. The core is comprised of four functional units: ? Experimental High Throughput Screening Unit (Experimental HTS lab) ? Virtual HTS and Molecular Modeling Unit (Virtual HTS lab) ? Chemical Intermediates and Library Synthesis Unit (Chemistry lab) ? Protein Crystallography Unit (Protein Crystallography, being added recently) Over the last five years, the core developed the Protein Crystallography Unit, which provides all services needed from cloning the DNA sequence to determining the crystal structure. The addition of the Protein Crystallography Unit led to the renaming of the HTS &Chemistry core to "Chemical Biology Core". In 2007, Moffitt recruited Ernst Schonbrunn, PhD, to lead this unit and serve as Co-Scientific Director with Dr. Guida. Under their joint leadership and due to the substantially increased demand for x-ray usage, additional equipment was acquired, including an upgraded X-ray generator in 2009. The Core requests CCSG Support of $363,941, which is 42% of its operational budget. Usage has grown to 22 active projects and Over 90% of usage is by Moffitt members and peer-reviewed.
The Chemical Biology core provides four fundamental services to enhance the research for Moffitt investigators that significantly impact the drug discovery process. Core has been highly successful in stimulating Cancer Center investigators grant applications in chemical biology approaches to cancer studies. In addition, the shared resource provides access to many kinds of equipment that are too expensive for the average laboratory to own individually.
|Chung, Brile; Stuge, Tor B; Murad, John P et al. (2014) Antigen-specific inhibition of high-avidity T cell target lysis by low-avidity T cells via trogocytosis. Cell Rep 8:871-82|
|Charbonneau, Bridget; Block, Matthew S; Bamlet, William R et al. (2014) Risk of ovarian cancer and the NF-*B pathway: genetic association with IL1A and TNFSF10. Cancer Res 74:852-61|
|Unrod, Marina; Simmons, Vani N; Sutton, Steven K et al. (2014) A randomized clinical trial of self-help intervention for smoking cessation: research design, interventions, and baseline data. Contemp Clin Trials 38:284-90|
|Osorio, Ana; Milne, Roger L; Kuchenbaecker, Karoline et al. (2014) DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet 10:e1004256|
|Padron, Eric; Yoder, Sean; Kunigal, Sateesh et al. (2014) ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. Blood 123:3675-7|
|Hampras, Shalaka S; Viscidi, Raphael P; Helzlsouer, Kathy J et al. (2014) Prospective study of seroreactivity to JC virus T-antigen and risk of colorectal cancers and adenomas. Cancer Epidemiol Biomarkers Prev 23:2591-6|
|Chen, Ning; Chon, Hye Sook; Xiong, Yin et al. (2014) Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel. Oncol Rep 31:376-83|
|Molife, L Rhoda; Yan, Li; Vitfell-Rasmussen, Joanna et al. (2014) Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J Hematol Oncol 7:1|
|Carvalho, Renato S; Fernandes, Vanessa C; Nepomuceno, Thales C et al. (2014) Characterization of LGALS3 (galectin-3) as a player in DNA damage response. Cancer Biol Ther 15:840-50|
|Rizwani, Wasia; Schaal, Courtney; Kunigal, Sateesh et al. (2014) Mammalian lysine histone demethylase KDM2A regulates E2F1-mediated gene transcription in breast cancer cells. PLoS One 9:e100888|
Showing the most recent 10 out of 108 publications